Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000017.xml
Exp Clin Endocrinol Diabetes 2021; 129(10): 699-704
DOI: 10.1055/a-1038-3883
DOI: 10.1055/a-1038-3883
Review
Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: An Overview
Niki Katsiki
1
First Department of Internal Medicine, Diabetes Centre, Division of
Endocrinology and Metabolism, AHEPA University Hospital, Thessaloniki,
Greece
,
Paschalis Steiropoulos
2
Department of Pneumonology, Democritus University of Thrace School of
Health Sciences, Alexandroupolis, Greece
,
Nikolaos Papanas
3
Diabetes Centre, Second Department of Internal Medicine, Democritus
University of Thrace, Alexandroupolis, Greece
,
Dimitri P. Mikhailidis
4
Department of Clinical Biochemistry, University College London, Royal
Free Hospital Campus, London, United Kingdom of Great Britain and Northern
Ireland
› Author Affiliations
Abstract
Chronic obstructive pulmonary disease (COPD) is a common disease with an increasing prevalence, characterised by persistent respiratory symptoms and airflow limitation. Apart from cigarette smoking, certain occupational and environmental exposures, low socioeconomic status and genetic factors may contribute to the pathogenesis of COPD. Comorbidities, e. g. diabetes mellitus (DM), can negatively affect quality of life, COPD outcomes and cardiovascular risk. The present narrative review considers the potential links between COPD and DM, such as systemic inflammation, oxidative stress, hypoxaemia and hyperglycaemia. The effects of antidiabetic drugs on lung function and COPD outcomes, as well as the possibility of common therapeutic modalities are also briefly considered. Further research is needed in this field to elucidate these relationships as well as their potential clinical implications in daily practice.
Publication History
Received: 21 May 2019
Received: 03 October 2019
Accepted: 30 October 2019
Article published online:
18 November 2019
© 2019. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 GOLD Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2019;
- 2 Lozano R, Naghavi M, Foreman K. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128
- 3 Adeloye D, Chua S, Lee C. et al Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Global Health 2015; 5: 020415
- 4 Lopez AD, Shibuya K, Rao C. et al. Chronic obstructive pulmonary disease: Current burden and future projections. Eur Respir J 2006; 27: 397-412
- 5 Lytras T, Kogevinas M, Kromhout H. et al. Occupational exposures and 20-year incidence of COPD: The European Community Respiratory Health Survey. Thorax 2018; 73: 1008-1015
- 6 Doiron D, de Hoogh K, Probst-Hensch N. et al. Air pollution, lung function and COPD: Results from the population-based UK Biobank study. Eur Respir J 2019; 54(1): pii: 1802140
- 7 Wang M, Aaron CP, Madrigano J. et al. Association between long-term exposure to ambient air pollution and change in quantitatively assessed emphysema and lung function. JAMA 2019; 322: 546-556
- 8 Celli BR, Decramer M, Wedzicha JA. et al ATS/ERS Task Force for COPD Research An official American Thoracic Society/European Respiratory Society statement: Research questions in COPD. Eur Respir Rev 2015; 24: 159-172
- 9 May SM, Li JT. Burden of chronic obstructive pulmonary disease: Healthcare costs and beyond. Allergy Asthma Proc 2015; 36: 4-10
- 10 Wacker ME, Jörres RA, Schulz H. et al. Direct and indirect costs of COPD and its comorbidities: Results from the German COSYCONET study. Respiratory Medicine 2016; 111: 39-46
- 11 Cavaillès A, Brinchault-Rabin G, Dixmier A. et al. Comorbidities of COPD. Eur Respir Rev 2013; 22: 454-475
- 12 Franssen FM, Rochester CL. Comorbidities in patients with COPD and pulmonary rehabilitation: Do they matter?. Eur Respir Rev 2014; 23: 131-141
- 13 Mannino DM, Thorn D, Swensen A. et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-969
- 14 Rogliani P, Lucà G, Lauro D. Chronic obstructive pulmonary disease and diabetes. COPD Research and Practice 2015; 1: 3
- 15 Lin CS, Liu CC, Yeh CC. et al. Diabetes risks and outcomes in chronic obstructive pulmonary disease patients: Two nationwide population-based retrospective cohort studies. PLoS One 2017; 12: e0181815
- 16 van der Molen T. Co-morbidities of COPD in primary care: Frequency, relation to COPD, and treatment consequences. Prim Care Respir J 2010; 19: 326-334
- 17 Rana J, Mittleman MA, Sheikh J. et al. Chronic obstructive pulmonary disease, asthma and risk of type 2 diabetes in women. Diabetes Care 2004; 27: 2478-2484
- 18 Lee CT, Mao IC, Lin CH. et al. Chronic obstructive pulmonary disease: a risk factor for type 2 diabetes: A nationwide population-based study. Eur J Clin Invest 2013; 43: 1113-1119
- 19 Mirrakhimov AE. Chronic obstructive pulmonary disease and glucose metabolism: A bitter sweet symphony. Cardiovasc Diabetol 2012; 11: 132
- 20 Rasmussen SM, Brok J, Backer V. et al. Association between chronic obstructive pulmonary disease and type 2 diabetes: A systematic review and meta-analysis. COPD 2018; 15: 526-535
- 21 Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: A result of 'overspill' of inflammatory mediators from the lungs? Review of the evidence. Thorax 2010; 65: 930-936
- 22 Tiengo A, Fadini GP, Avogaro A. The metabolic syndrome, diabetes and lung dysfunction. Diabetes Metab 2008; 34: 447-454
- 23 Burt MG, Roberts GW, Aguilar-Loza NR. et al. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab 2011; 96: 1789-1796
- 24 Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010; 123: 1001-1006
- 25 Herth FJ, Bramlage P, Müller-Wieland D. Current perspectives on the contribution of inhaled corticosteroids to an increased risk for diabetes onset and progression in patients with chronic obstructive pulmonary disease. Respiration 2015; 89: 66-75
- 26 Caughey GE, Preiss AK, Vitry AI. et al. Comorbid diabetes and COPD: Impact of corticosteroid use on diabetes complications. Diabetes Care 2013; 36: 3009-3014
- 27 Parappil A, Depczynski B, Collett P. et al. Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPD. Respirology 2010; 15: 918-922
- 28 Baker EH, Janaway CH, Philips BJ. et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 2006; 61: 284-289
- 29 Gläser S, Krüger S, Merkel M. et al. Chronic obstructive pulmonary disease and diabetes mellitus: A systematic review of the literature. Respiration 2015; 89: 253-264
- 30 Koskela HO, Salonen PH, Romppanen J. et al. A history of diabetes but not hyperglycaemia during exacerbation of obstructive lung disease has impact on long-term mortality: a prospective, observational cohort study. BMJ Open 2015; 5: e006794
- 31 Hsu IL, Lu CL, Li CC. et al. Population-based cohort study suggesting a significantly increased risk of developing chronic obstructive pulmonary disease in people with type 2 diabetes mellitus. Diabetes Res Clin Pract 2018; 138: 66-74
- 32 Walter RE, Beiser A, Givelber RJ. et al. Association between glycemic state and lung function: The Framingham Heart Study. Am J Respir Crit Care Med 2003; 167: 911-916
- 33 Lawlor DA, Ebrahim S, Smith GD. Associations of measures of lung function with insulin resistance and Type 2 diabetes: Findings from the British Women’s Heart and Health Study. Diabetologia 2004; 47: 195-203
- 34 McKeever TM, Weston PJ, Hubbard R. et al. Lung function and glucose metabolism: An analysis of data from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2005; 101: 546-556
- 35 Lange P, Parner J, Sohr P. et al. Copenaghen City Heart Study: Longitudinal analysis of ventilatory capacity in diabetic and nondiabetic adults. Eur Respir J 2002; 20: 1406-1412
- 36 Yeh HC, Punjabi NM, Wang NY. et al. Cross-sectional and prospective study of lung function in adults with type 2 diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 2008; 31: 741-746
- 37 Mekov EV, Slavova YG, Genova MP. et al. Diabetes mellitus type 2 in hospitalized COPD patients: Impact on quality of life and lung function. Folia Med (Plovdiv) 2016; 58: 36-41
- 38 Chiu HT, Li TC, Li CI. et al. Visit-to-visit glycemic variability is a strong predictor of chronic obstructive pulmonary disease in patients with type 2 diabetes mellitus: Competing risk analysis using a national cohort from the Taiwan diabetes study. PLoS One 2017; 12: e0177184
- 39 Li CI, Li TC, Liu CS. et al. Extreme values of hemoglobin a1c are associated with increased risks of chronic obstructive pulmonary disease in patients with type 2 diabetes: A competing risk analysis in National Cohort of Taiwan diabetes study. Medicine (Baltimore) 2015; 94: e367
- 40 Klein OL, Krishnan JA, Glick S. et al. Systematic review of the association between lung function and Type 2 diabetes mellitus. Diabet Med 2010; 27: 977-987
- 41 Cazzola M, Rogliani P, Calzetta L. et al. Targeting mechanisms linking copd to type 2 diabetes mellitus. Trends Pharmacol Sci 2017; 38: 940-951
- 42 Maddatu J, Anderson-Baucum E, Evans-Molina C. Smoking and the risk of type 2 diabetes. Transl Res 2017; 184: 101-107
- 43 Bellou V, Belbasis L, Tzoulaki I. et al. Risk factors for type 2 diabetes mellitus: An exposure-wide umbrella review of meta-analyses. PLoS One 2018; 13: e0194127
- 44 Meteran H, Backer V, Kyvik KO. et al. Comorbidity between chronic obstructive pulmonary disease and type 2 diabetes: A nation-wide cohort twin study. Respir Med 2015; 109: 1026-1030
- 45 Aurora RN, Punjabi NM. Obstructive sleep apnoea and type 2 diabetes mellitus: A bidirectional association. Lancet Respir Med 2013; 1: 329-338
- 46 Rayner LH, McGovern AP, Sherlock J. et al. Type 2 diabetes: A protective factor for COPD?. Prim Care Diabetes 2018; 12: 438-444
- 47 Vitry AI, Roughead EE, Preiss AK. et al. Influence of comorbidities on therapeutic progression of diabetes treatment in Australian veterans: A cohort study. PLoS One 2010; 5: e14024
- 48 Kim HJ, Lee JY, Jung HS. et al. The impact of insulin sensitisers on lung function in patients with chronic obstructive pulmonary disease and diabetes. Int J Tuberc Lung Dis 2010; 14: 362-367
- 49 Tseng CH. Metformin and risk of chronic obstructive pulmonary disease in diabetes patients. Diabetes Metab 2019; 45: 184-190
- 50 https://www.endocrine-abstracts.org/ea/0041/ea0041EP543 Last accessed 26 August 2019
- 51 Bishwakarma R, Zhang W, Lin YL. et al. Metformin use and health care utilization in patients with coexisting chronic obstructive pulmonary disease and diabetes mellitus. Int J Chron Obstruct Pulmon Dis 2018; 13: 793-800
- 52 Ho TW, Huang CT, Tsai YJ. et al. Metformin use mitigates the adverse prognostic effect of diabetes mellitus in chronic obstructive pulmonary disease. Respir Res 2019; 20: 69
- 53 Hitchings AW, Archer JR, Srivastava SA. et al. Safety of metformin in patients with chronic obstructive pulmonary disease and type 2 diabetes mellitus. COPD 2015; 12: 126-131
- 54 Yen FS, Chen W, Wei JC. et al. Effects of metformin use on total mortality in patients with type 2 diabetes and chronic obstructive pulmonary disease: A matched-subject design. PLoS One 2018; 13: e0204859
- 55 Mendy A, Gopal R, Alcorn JF. et al. Reduced mortality from lower respiratory tract disease in adult diabetic patients treated with metformin. Respirology 2019; 24: 646-651
- 56 Sexton P, Metcalf P, Kolbe J. Respiratory effects of insulin sensitisation with metformin: A prospective observational study. COPD 2014; 11: 133-142
- 57 Simental-Mendia LE, Pirro M, Atkin SL. et al. Effect of metformin on plasma fibrinogen concentrations: A systematic review and meta-analysis of randomized placebo-controlled trials. Curr Pharm Des 2018; 24: 1034-1040
- 58 Papazafiropoulou A, Papanas N, Pappas S. et al. Effects of oral hypoglycemic agents on platelet function. J Diabetes Complications 2015; 29: 846-851
- 59 Fimognari FL, Scarlata S, Conte ME. et al. Mechanisms of atherothrombosis in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008; 3: 89-96
- 60 Malerba M, Clini E, Malagola M. et al. Platelet activation as a novel mechanism of atherothrombotic risk in chronic obstructive pulmonary disease. Expert Rev Hematol 2013; 6: 475-483
- 61 Lakshmi SP, Reddy AT, Reddy RC. Emerging pharmaceutical therapies for COPD. Int J Chron Obstruct Pulmon Dis 2017; 12: 2141-2156
- 62 Papanas N, Katsiki N, Hatzitolios AI. et al. Pioglitazone: A valuable component of combination therapy for type 2 diabetes mellitus. Expert Opin Pharmacother 2011; 12: 1457-1461
- 63 Katsiki N, Mikhailidis DP. Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial. J Diabetes Complications 2017; 31: 1-3
- 64 Belvisi MG, Hele DJ, Birrell MA. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur J Pharmacol 2006; 533: 101-109
- 65 Nader MA. Inhibition of airway inflammation and remodeling by sitagliptin in murine chronic asthma. Int Immunopharmacol 2015; 29: 761-769
- 66 Tai H, Wang MY, Zhao YP. et al. The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy. Medicine (Baltimore) 2016; 95: e4541
- 67 Chilton R, Wyatt J, Nandish S. et al. Cardiovascular comorbidities of type 2 diabetes mellitus: Defining the potential of glucagon like peptide-1-based therapies. Am J Med 2011; 124: S35-S53
- 68 Viby NE, Isidor MS, Buggeskov KB. et al. Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology 2013; 154: 4503-4511
- 69 Huang J, Yi H, Zhao C. et al. Glucagon-like peptide-1 receptor (GLP-1R) signaling ameliorates dysfunctional immunity in COPD patients. Int J Chron Obstruct Pulmon Dis 2018; 13: 3191-3202
- 70 Oztay F, Sancar-Bas S, Gezginci-Oktayoglu S. et al. Exendin-4partly ameliorates hyperglycemia-mediated tissue damage in lungs of streptozotocin-induced diabetic mice. Peptides 2018; 99: 99-107
- 71 Gerards MC, Venema GE, Patberg KW. et al. Dapagliflozin for prednisone-induced hyperglycaemia in acute exacerbation of chronic obstructive pulmonary disease. Diabetes Obes Metab 2018; 20: 1306-1310
- 72 Yaribeygi H, Katsiki N, Butler AE. et al. Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys. Drug Discov Today 2019; 24: 256-262
- 73 Yaribeygi H, Butler AE, Atkin SL. et al. Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways. J Cell Physiol 2018; 234: 223-230
- 74 Batzias K, Antonopoulos AS, Oikonomou E. et al. Effects of newer antidiabetic drugs on endothelial function and arterial stiffness: A systematic review and meta-analysis. J Diabetes Res 2018; 1232583
- 75 Katsiki N, Mikhailidis DP, Theodorakis MJ. Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their role in cardiometabolic risk management. Curr Pharm Des 2017; 23: 1522-1532
- 76 Katsiki N, Athyros VG, Mikhailidis DP. Cardiovascular effects of sodium-glucose cotransporter 2 inhibitors: Multiple actions. Curr Med Res Opin 2016; 32: 1513-1514
- 77 Verberne LDM, Leemrijse CJ, Swinkels ICS. et al. Overweight in patients with chronic obstructive pulmonary disease needs more attention: A cross-sectional study in general practice. NPJ Prim Care Respir Med 2017; 27: 63
- 78 Zammit C, Liddicoat H, Moonsie I. et al. Obesity and respiratory diseases. Int J Gen Med 2010; 3: 335-343
- 79 Steuten LM, Creutzberg EC, Vrijhoef HJ. et al. COPD as a multicomponent disease: Inventory of dyspnoea, underweight, obesity and fat free mass depletion in primary care. Prim Care Respir J 2006; 15: 84-91
- 80 Luo Y, Zhou L, Li Y. et al. Fat-Free Mass index for evaluating the nutritional status and disease severity in COPD. Respir Care 2016; 61: 680-688
- 81 Vorrink SN, Kort HS, Troosters T. et al. Level of daily physical activity in individuals with COPD compared with healthy controls. Respir Res 2011; 12: 33
- 82 Watz H, Waschki B, Kirsten A. et al. The metabolic syndrome in patients with chronic bronchitis and COPD: Frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009; 136: 1039-1046
- 83 Franssen FM, O'Donnell DE, Goossens GH. et al. Obesity and the lung: 5. Obesity and COPD. Thorax 2008; 63: 1110-1117
- 84 Tkacova R. Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives. Mediators Inflamm 2010; 2010: 585989
- 85 McClean KM, Kee F, Young IS. et al. Obesity and the lung: 1. Epidemiology. Thorax 2008; 63: 649-654
- 86 Poulain M, Doucet M, Major GC. et al. The effect of obesity on chronic respiratory diseases: Pathophysiology and therapeutic strategies. CMAJ 2006; 174: 1293-1299
- 87 Guenette JA, Jensen D, O'Donnell DE. Respiratory function and the obesity paradox. Curr Opin Clin Nutr Metab Care 2010; 13: 618-624
- 88 Röhling M, Herder C, Roden M. et al. Effects of long-term exercise interventions on glycaemic control in type 1 and type 2 diabetes: a systematic review. Exp Clin Endocrinol Diabetes 2016; 124: 487-494
- 89 Katsiki N, Ntaios G, Vemmos K. Stroke, obesity and gender: A review of the literature. Maturitas 2011; 69: 239-243
- 90 Morse SA, Gulati R, Reisin E. The obesity paradox and cardiovascular disease. Curr Hypertens Rep 2010; 12: 120-126
- 91 Chittal P, Babu AS, Lavie CJ. Obesity paradox: Does fat alter outcomes in chronic obstructive pulmonary disease?. COPD 2015; 12: 14-18
- 92 Marti S, Muñoz X, Rios J. et al. Body weight and comorbidity predict mortality in COPD patients treated with oxygen therapy. Eur Respir J 2006; 27: 689-696
- 93 Spelta F, FrattaPasini AM, Cazzoletti L. et al. Body weight and mortality in COPD: Focus on the obesity paradox. Eat Weight Disord 2018; 23: 15-22
- 94 Lainscak M, von Haehling S, Doehner W. et al. Body mass index and prognosis in patients hospitalised with acute exacerbation of chronic obstructive pulmonary disease. J Cachex Sarcopenia Muscle 2011; 2: 81-86
- 95 McGhan R, Radcliff T, Fish R. et al. Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest 2007; 132: 1748-1755
- 96 Prescott E, Almdal T, Mikkelsen KL. et al. Prognostic value of weight change in chronic obstructive pulmonary disease: Results from the Copenhagen City Heart Study. Eur Respir J 2002; 20: 539-544
- 97 Guo Y, Zhang T, Wang Z. et al. Body mass index and mortality in chronic obstructive pulmonary disease: A dose-response meta-analysis. Medicine (Baltimore) 2016; 95: e4225
- 98 Petersmann A, Nauck M, Müller-Wieland D. et al. Definition, classification and diagnosis of diabetes mellitus. Exp Clin Endocrinol Diabetes 2018; 126: 406-410